Skip to content

Inspection Record

Biomat USA Inc — FDA 483 Findings

US FDAInspected 2026-04-14Published 2026-10-20 4 findingsOther quality systemMaterial and supplier controlDeviation, CAPA, and investigation

Inspectors Elyshia Q DanaherThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Other quality system

Failure to maintain donor, processing and general records.

2Material and supplier control

Failure to present educational material to the donor in an appropriate form and in a manner designed to be understood by the donor.

3Deviation, CAPA, and investigation

Failure to perform a thorough investigation and makea record of the conclusions and follow-up of an unexplained discrepancy.

4Material and supplier control

Written standard operating procedures including all steps to be followed in the collection and storage of blood and blood components for were not always followed.

Similar findings at other companies

GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.

A record as of the US FDA document published on 2026-10-20. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Other records for this company

Biomat USA Inc findings history — including this company's other documentsAll US FDA findings US FDA documents, 2026 Go to Findings search
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.